0001415889-24-002957.txt : 20240207 0001415889-24-002957.hdr.sgml : 20240207 20240207180011 ACCESSION NUMBER: 0001415889-24-002957 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240205 FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NIVEN RALPH CENTRAL INDEX KEY: 0001168060 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 24606145 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-02072024_060201.xml X0508 4 2024-02-05 0001798749 Aerovate Therapeutics, Inc. AVTE 0001168060 NIVEN RALPH C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false CHIEF SCIENTIFIC OFFICER 1 Common Stock 2024-02-05 4 M 0 1400 1.74 A 3009 D Common Stock 2024-02-05 4 M 0 3200 2.14 A 6209 D Common Stock 2024-02-05 4 S 0 4600 17.4455 D 1609 D Stock Option (Right to Buy) 1.74 2024-02-05 4 M 0 900 0 D 2030-09-03 Common Stock 900 13308 D Stock Option (Right to Buy) 1.74 2024-02-05 4 M 0 500 0 D 2030-09-03 Common Stock 500 9088 D Stock Option (Right to Buy) 2.14 2024-02-05 4 M 0 500 0 D 2031-04-01 Common Stock 500 10894 D Stock Option (Right to Buy) 2.14 2024-02-05 4 M 0 1200 0 D 2031-04-01 Common Stock 1200 34908 D Stock Option (Right to Buy) 2.14 2024-02-05 4 M 0 1500 0 D 2031-04-01 Common Stock 1500 41732 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. /s/ George A. Eldridge, Attorney-in-Fact 2024-02-07